page banner

OUR JOURNEY

Key Milestones

2014

  • Establishment of Shenzhen HaploX

2015

  • Establishment of Shenzhen Lab
  • Launched the Chinese Cancer Sequencing Project to perform early cancer screening for 10,000 people
  • Completed the Series Angel Financing

2016

  • Certified as National High and New Technology Enterprise
  • Completed the Series A Financing

2017

  • Establishment of Jiangxi Lab
  • Completed the Series A+ Financing

2018

  • Certified as Guangdong Tumor Liquid Biopsy Engineering Technology Research Center
  • Certified as Innovation and Experiment Center for Postdoctoral Fellows
  • Commercialized HapOnco® WESPlus® NGS Assay
  • Completed the Series B Financing
  • Certified as Operating Base of the High-level Creative Talents Practice Programme of Nanshan District of Shenzhen

2019

  • Launched the Liver Exploration Project
  • Awarded as 2019 Shenzhen High Tech High Growth Top 20
  • Awarded as 2019 Shenzhen Leading Biotech Companies Top 20 Pioneer Enterprise
  • Certified as Guangdong New R&D Institution
  • Shenzhen Lab obtained the CAP Laboratory Accreditation from the College of American Pathologists

2020

  • Establishment of Tianjin Lab
  • Commercialized HapOnco® StarPanel™ NGS Assay
  • Completed the Series B+ Financing

2021

  • HapOnco® LungCDx EGFR/ALK NGS Testing Kit was approved by NMPA as a Class III medical device
  • Establishment of Shenzhen Tumor Gene Detection Engineering Technology Center
  • Establishment of Shenzhen Academician (Expert) Workstation
  • Establishment of Hapmic
  • Completed the Series C Financing

2022

  • Accompanion software of HapOnco® LungCDx EGFR/ALK NGS Testing Kit approved by Guangdong branch of the NMPA as a Class II medical device
  • Establishment of Shenzhen Future Lab
  • Awarded as Guangdong Patent Golden Award
  • Certified as National Specialized and New 'Small Giant' Enterprise
  • Completed the Onshore Series D Financing

To be continued